During the past decade, Institute of Rheumatology conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 23 clinical trials were completed, i.e. on average, 92% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 14 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute of Rheumatology" #1 sponsor was "Pfizer" with 9 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Rheumatology" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Charite University, Berlin, Germany" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "European Union" with 1 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Institute of Rheumatology" are "Rheumatoid Arthritis" (16 trials), "Lupus Erythematosus, Systemic" (5 trials), "Arthritis, Rheumatoid" (3 trials), "Systemic Lupus Erythematosus" (3 trials) and "Lupus Nephritis" (2 trials). Many other conditions were trialed in "Institute of Rheumatology" in a lesser frequency.

Most popular intervention types in "Institute of Rheumatology" are "Drug" (30 trials), "Biological" (7 trials) and "Other" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Adalimumab" (2 trials), "BI 695501" (2 trials), "Baricitinib" (2 trials) and "GDC-0853" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Rheumatology" are 36 trials for "All" genders.

Currently, there are NaN active trials in "Institute of Rheumatology". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 26 completed trials in Institute of Rheumatology, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Rheumatology, 0 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".